ABSTRACT
Objective: to document the outcomes of open mesh repair in the management of various Hernias
Study design: a descriptive case-series study
Sampling technique: non-probability purposive
Place and duration of study: department of Surgery, Unit-I Chandka Medical College Hospital, Larkana, from July 2003 to June 2008
Patients and methods: two hundred and eighty patients of hernia operated by sublay mesh repair were analyzed for postoperative outcomes as pain, surgical site infection, hematoma/seroma, sinus formation and recurrence. Data were collected by filling specially designed proforma for each patient. Follow up visits were scheduled at three weeks, six weeks, three months and six months postoperatively
Results: polypropylene sublay mesh repair was performed in 280 patients of hernia comprising of 174 males and 106 females with male to female ratio of 1.6:1. Age ranged from 20 to 78 years, mean 51 years. Inguinoscrotal hernia was the commonest type [52.5%], followed by periumbilical hernia [26.25%] and incisional hernia [13%]. Postoperatively 254 [91%] patients had uneventful recovery, 15 [5.3%] had surgical site infection, while 11 [3.9%] patients developed seroma. Neither recurrence nor chronic discharging sinus was noted
Conclusion: open mesh repair for hernia is a safe and effective technique, associated with low morbidity. Technique has proved to be simple and easy to perform, with minimal postoperative pain and early mobilization
ABSTRACT
To record the effect of pyrazinamide on uric acid in patients of tuberculosis. Design: Descriptive and observational study. Place and Duration of Study: Chandka Medical College Hospital, Larkana from February 2000 to January 2003. Patients and All patients receiving anti-tuberculosis drugs with pyrazinamide were included. Serum uric acid levels were monitored at weeks 0, 2, 8 and 12 of therapy. Serum creatinine was done at weeks 0, 8 and 12. Results were reported on 216 patients. Mean uric acid and creatinine levels at the start of therapy, i.e., week '0' were 5.07 '0.57 mg/dl and 0.87 '0.11 mg/dl respectively. The results show significant increase in uric acid levels from week '0' to week '2', at the end of week '8', the levels remained elevated and there was no statistical significant difference from that at week '2'. The uric acid levels reduced at week '12' after pyrazinamide was stopped and the difference was significant. Despite that renal function steadily improved with the treatment of tuberculosis to the extent that comparable pre-treatment values were obtained at the end of treatment. Anti-tuberculous therapy with pyrazinamide affects the uric acid levels early. This change is reversible after the withdrawal of the agent